CL2022001323A1 - Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x - Google Patents
Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático xInfo
- Publication number
- CL2022001323A1 CL2022001323A1 CL2022001323A CL2022001323A CL2022001323A1 CL 2022001323 A1 CL2022001323 A1 CL 2022001323A1 CL 2022001323 A CL2022001323 A CL 2022001323A CL 2022001323 A CL2022001323 A CL 2022001323A CL 2022001323 A1 CL2022001323 A1 CL 2022001323A1
- Authority
- CL
- Chile
- Prior art keywords
- hepatic
- receptor agonists
- oxadiazole derivatives
- compound
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940061P | 2019-11-25 | 2019-11-25 | |
| US202063106293P | 2020-10-27 | 2020-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001323A1 true CL2022001323A1 (es) | 2023-03-24 |
Family
ID=73654860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001323A CL2022001323A1 (es) | 2019-11-25 | 2022-05-19 | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x |
Country Status (22)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022243907A1 (en) * | 2021-05-20 | 2022-11-24 | Novartis Ag | Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione |
| WO2022249006A1 (en) * | 2021-05-24 | 2022-12-01 | Novartis Ag | Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists |
| KR102882404B1 (ko) | 2022-10-28 | 2025-11-06 | (주)케이메디켐 | 신규 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201120016A (en) | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| EP2753608A1 (en) * | 2011-09-08 | 2014-07-16 | Allergan, Inc. | 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| WO2015187840A2 (en) | 2014-06-03 | 2015-12-10 | Duke University | Methods and formulations for treatment of ocular disorders |
| WO2020123869A1 (en) | 2018-12-13 | 2020-06-18 | eyeNOS, Inc. | Lxr agonist in topical ophthalmic formulation for treatment of dry-eye disorder |
-
2020
- 2020-11-20 PY PY202002077235A patent/PY2077235A/es unknown
- 2020-11-20 UY UY0001038964A patent/UY38964A/es not_active Application Discontinuation
- 2020-11-23 MX MX2022006151A patent/MX2022006151A/es unknown
- 2020-11-23 CR CR20220227A patent/CR20220227A/es unknown
- 2020-11-23 TW TW109140930A patent/TW202132289A/zh unknown
- 2020-11-23 CA CA3157657A patent/CA3157657A1/en active Pending
- 2020-11-23 IL IL291958A patent/IL291958A/en unknown
- 2020-11-23 AU AU2020394597A patent/AU2020394597B2/en not_active Expired - Fee Related
- 2020-11-23 JP JP2022529931A patent/JP2023503320A/ja active Pending
- 2020-11-23 PH PH1/2022/551248A patent/PH12022551248A1/en unknown
- 2020-11-23 US US17/101,510 patent/US11427586B2/en active Active
- 2020-11-23 KR KR1020227020461A patent/KR20220106778A/ko not_active Ceased
- 2020-11-23 EP EP20817082.9A patent/EP4065228A1/en not_active Withdrawn
- 2020-11-23 WO PCT/IB2020/061053 patent/WO2021105857A1/en not_active Ceased
- 2020-11-23 BR BR112022009942A patent/BR112022009942A2/pt not_active Application Discontinuation
- 2020-11-23 CN CN202080081467.7A patent/CN114746149A/zh active Pending
- 2020-11-23 PE PE2022000828A patent/PE20221785A1/es unknown
-
2022
- 2022-05-19 CO CONC2022/0006645A patent/CO2022006645A2/es unknown
- 2022-05-19 EC ECSENADI202240362A patent/ECSP22040362A/es unknown
- 2022-05-19 CL CL2022001323A patent/CL2022001323A1/es unknown
- 2022-05-20 DO DO2022000107A patent/DOP2022000107A/es unknown
- 2022-05-23 JO JOP/2022/0124A patent/JOP20220124A1/ar unknown
- 2022-06-06 US US17/805,487 patent/US20220340573A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023503320A (ja) | 2023-01-27 |
| US20220340573A1 (en) | 2022-10-27 |
| IL291958A (en) | 2022-06-01 |
| PH12022551248A1 (en) | 2023-09-11 |
| ECSP22040362A (es) | 2022-06-30 |
| MX2022006151A (es) | 2022-08-02 |
| EP4065228A1 (en) | 2022-10-05 |
| TW202132289A (zh) | 2021-09-01 |
| CN114746149A (zh) | 2022-07-12 |
| CA3157657A1 (en) | 2021-06-03 |
| CR20220227A (es) | 2022-06-15 |
| AU2020394597B2 (en) | 2024-03-14 |
| KR20220106778A (ko) | 2022-07-29 |
| BR112022009942A2 (pt) | 2022-08-09 |
| DOP2022000107A (es) | 2022-06-15 |
| UY38964A (es) | 2021-06-30 |
| CO2022006645A2 (es) | 2022-05-31 |
| JOP20220124A1 (ar) | 2022-05-23 |
| WO2021105857A1 (en) | 2021-06-03 |
| US20220064164A1 (en) | 2022-03-03 |
| AU2020394597A1 (en) | 2022-06-02 |
| PE20221785A1 (es) | 2022-11-22 |
| PY2077235A (es) | 2022-10-31 |
| US11427586B2 (en) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022006645A2 (es) | Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x | |
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| ECSP21080535A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| PE20191541A1 (es) | Composiciones y metodos para inhibir la accion de la arginasa | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| PY1737795A (es) | Solución de dexmedetomidina lista para el uso, premezclada, esterilizable por calor, envasada en un recipiente de plástico flexible | |
| CL2009000860A1 (es) | Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer. | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| CL2021003455A1 (es) | Análogos de 3-(5-meti l-1 ,3-tiazol-2-1 l)-n--{( 1 r)-1-[2-(trifluoro-metil)pirimidin-5-il]etil}benzamida | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| MX389553B (es) | Composicion para incrementar la expresion de pgc-1alfa | |
| MX2021005240A (es) | Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| ECSP19044591A (es) | Amidas aromáticas de ácido carboxílico como antagonistas del receptor b1 de la bradiquinina | |
| CO2022003583A2 (es) | Compuestos de curcumina y aminoácidos básicos | |
| CO2024001017A2 (es) | Compuestos terapéuticos y procedimientos | |
| MX2023011377A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos. | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| DOP2025000235A (es) | Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo | |
| CL2019001618A1 (es) | Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar. |